Quick Answer
TG THERAPEUTICS, INC. reported Earnings Per Share Diluted of $2.77 per share for the year ending 2025.
- TG THERAPEUTICS, INC. showed an increase of +1,746.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from TG THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $0.69 (loss) per share | Q2 2021: $0.59 (loss) per share | Q3 2021: $0.65 (loss) per share | Q1 2022: $0.51 (loss) per share | Q2 2022: $0.30 (loss) per share | Q3 2022: $0.26 (loss) per share | Q1 2023: $0.28 (loss) per share | Q2 2023: $0.34 (loss) per share | Q3 2023: $0.73 per share | Q1 2024: $0.07 (loss) per share | Q2 2024: $0.04 per share | Q3 2024: $0.02 per share | Q1 2025: $0.03 per share | Q2 2025: $0.17 per share | Q3 2025: $2.43 per share.
- Over the full 6 years of available data (2020 to 2025), TG THERAPEUTICS, INC.'s Earnings Per Share Diluted has grown by 214.5%.
- Historical annual values: Fiscal year 2025: $2.77 per share | Fiscal year 2024: $0.15 per share | Fiscal year 2023: $0.09 per share | Fiscal year 2022: $1.65 (loss) per share | Fiscal year 2021: $2.63 (loss) per share | Fiscal year 2020: $2.42 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: